search

1-20 of 48

Save search

Sort by

Sort Order Select

2 3

Journal Article

TRLS-14. PNOC022 REPORT: A COMBINATION THERAPY TRIAL USING AN ADAPTIVE PLATFORM DESIGN FOR PATIENTS WITH DIFFUSE MIDLINE GLIOMA AT INITIAL DIAGNOSIS, POST-RADIATION THERAPY, OR PROGRESSION

PDF

Cassie Kline and others

Neuro-Oncology, Volume 26, Issue Supplement_4, June 2024, Page 0, https://doi.org/10.1093/neuonc/noae064.167

Published: 18 June 2024

Journal Article

TMET-02. CLINICAL EFFICACY OF ONC201 IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMAS IS DRIVEN BY DISRUPTION OF INTEGRATED METABOLIC AND EPIGENETIC PATHWAYS

PDF

Sriram Venneti and others

Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v272, https://doi.org/10.1093/neuonc/noad179.1046

Published: 10 November 2023

Journal Article

CTNI-84. PNOC022: A COMBINATION THERAPY TRIAL USING AN ADAPTIVE PLATFORM DESIGN FOR PATIENTS WITH DIFFUSE MIDLINE GLIOMAS (DMGS) AT INITIAL DIAGNOSIS, POST-RADIATION THERAPY AND AT TIME OF PROGRESSION

PDF

Cassie Kline and others

Neuro-Oncology, Volume 25, Issue Supplement_5, November 2023, Page v97, https://doi.org/10.1093/neuonc/noad179.0365

Published: 10 November 2023

Journal Article

CTNI-68. FIREFLY-1 (PNOC026): PHASE 2 STUDY OF PAN-RAF INHIBITOR TOVORAFENIB IN PEDIATRIC AND YOUNG ADULT PATIENTS WITH RAF-ALTERED RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA OR ADVANCED SOLID TUMORS

PDF

Lindsay Kilburn and others

Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Page vii89, https://doi.org/10.1093/neuonc/noac209.333

Published: 14 November 2022

Journal Article

CTNI-61. CLINICAL EFFICACY AND PREDICTIVE BIOMARKERS OF ONC201 IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA

PDF

Abed Rahman Kawakibi and others

Neuro-Oncology, Volume 24, Issue Supplement_7, November 2022, Pages vii86–vii87, https://doi.org/10.1093/neuonc/noac209.326

Published: 14 November 2022

Journal Article

LTBK-04. LATE BREAKING ABSTRACT: MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: a multi-institutional phase II and target validation study

PDF

Nathan Robison and others

Neuro-Oncology, Volume 24, Issue Supplement_1, June 2022, Pages i191–i192, https://doi.org/10.1093/neuonc/noac079.716

Published: 13 June 2022

Journal Article

LTBK-05. CLINICAL EFFICACY OF ONC201 IN RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA PATIENTS

PDF

Isabel Arrillaga-Romany and others

Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi230, https://doi.org/10.1093/neuonc/noab196.925

Published: 19 November 2021

Journal Article

BIOM-28. SERIAL PLASMA AND CSF CELL-FREE TUMOR DNA (cf-tDNA) TRACKING IN DIFFUSE MIDLINE GLIOMA PATIENTS UNDERGOING TREATMENT WITH ONC201

PDF

Evan Cantor and others

Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Pages vi16–vi17, https://doi.org/10.1093/neuonc/noab196.059

Published: 12 November 2021

Journal Article

CTNI-27. SINGLE AGENT ACTIVITY OF ONC201 IN NON-MIDLINE H3 K27M-MUTANT DIFFUSE GLIOMAS

PDF

Yazmin Odia and others

Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi65, https://doi.org/10.1093/neuonc/noab196.252

Published: 12 November 2021

Journal Article

CTNI-36. SAFETY OF ONC201 ADMINISTERED TWO CONSECUTIVE DAYS PER WEEK IN PEDIATRIC H3 K27M-MUTANT GLIOMA PATIENTS

PDF

Sharon Gardner and others

Neuro-Oncology, Volume 23, Issue Supplement_6, November 2021, Page vi67, https://doi.org/10.1093/neuonc/noab196.261

Published: 12 November 2021

Journal Article

EPCT-03. SERIAL PLASMA AND CSF CELL-FREE TUMOR DNA (CF-TDNA) TRACKING IN DIFFUSE MIDLINE GLIOMA PATIENTS UNDERGOING TREATMENT WITH ONC201

PDF

Evan Cantor and others

Neuro-Oncology, Volume 23, Issue Supplement_1, June 2021, Pages i46–i47, https://doi.org/10.1093/neuonc/noab090.189

Published: 01 June 2021

Journal Article

DIPG-52. PHASE I CLINICAL TRIAL OF ONC201 IN PEDIATRIC H3 K27M-MUTANT GLIOMA OR NEWLY DIAGNOSED DIPG

PDF

Sharon Gardner and others

Neuro-Oncology, Volume 22, Issue Supplement_3, December 2020, Page iii297, https://doi.org/10.1093/neuonc/noaa222.097